Company profilePharmaceutical#534 of 1,318 in Pakistan✓ No DRAP alerts

CUREXA HEALTH (PVT.) LIMITED

Pharmaceutical company · 24 brands · 15 molecules

Ranked #99 of 137 companies in Anti-Infectives

24 registered products 27 pharmaceutical brands 15 distinct molecules 0 DRAP alerts

Company overview

24
registered products
27
pharmaceutical brands
15
distinct molecules
2
therapeutic classes
0
DRAP alerts

CUREXA HEALTH (PVT.) LIMITED is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 24 product registrations across 15 distinct molecules. Its portfolio is concentrated in Anti-Infectives and Other Beta-Lactam, Cephalosporins & Penems. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by CUREXA

6 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

6
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20266

Top molecules by brand count

Cefixime4 brands
Cephalexin1 brand
Cefixime ...... 200 Mg1 brand
Ceftriaxone ...... 2 G1 brand
Ceftriaxone ...... 1 Gm1 brand

Therapeutic classes

Anti-Infectives · 1Other Beta-Lactam, Cephalosporins & Penems · 1

Conditions treated

General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official30 products · Rs 110.89 – Rs 897.61
DVAGO1 products · Rs 448 – Rs 448
Servaid5 products · Rs 109 – Rs 310
Median across source: Rs 339.09

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

AKSON PHARMACEUTICALS (PVT) LTD. holds 51 molecules not in this portfolio
000 I.UAmikacinArtemetherAtropineAzithromycinCefotaxime
MEDICAIDS PAKISTAN (PVT) LTD. holds 43 molecules not in this portfolio
AmikacinArtemetherArtemether LumefentrineAzithromycinAzithromycin UspCefotaxime
AMROS PHARMACEUTICALS. holds 35 molecules not in this portfolio
AmlodipineAmoxicillinAmoxycillinAmoxycillin CapsuleAmrofen TabletArtemether

Get the full profile for CUREXA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.